Could Blue-Chip Bristol-Myers Squibb's (NYSE: BMY) Shares Rise More than 40% by Early 2018?

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

Bristol Myers Squibb Co / Equity Bottom-Up

In our first report on <a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb Co (BMY US)</a>, we presented our bullish contrarian thesis and considered the common stock undervalued for long-term investors with a first price target of US$74. We maintain our first price target after listening to the Q3 2016 earnings transcript.<a href="https://www.smartkarma.com/insights/could-blue-chip-bristol-myers-squibb-s-nyse-bmy-shares-rise-more-than-40-by-early-2018" target="_blank">Link to first report.</a>Some highlights of the Q3 earnings are:<ul>
<li>Global revenue was US$4.9 billion, 21% YOY growth.</li>
<li>
Update on Opdivo (anti-PD1 antibody in various cancers), the flagship revenue driver:<ul><li>Opdivo demand…</li></ul>
</li>
</ul>

In our first report on Bristol Myers Squibb Co (BMY US), we presented our bullish contrarian thesis and considered the common stock undervalued for long-term investors with a first price target of US$74. We maintain our first price target after listening to the Q3 2016 earnings transcript.Link to first report.Some highlights of the Q3 earnings are:
Global revenue was US$4.9 billion, 21% YOY growth.

Update on Opdivo (anti-PD1 antibody in various cancers), the flagship revenue driver:Opdivo demand…



Revisiting the Bristol-Myers Squibb (BMY US) Bullish Investment Thesis After the Q3 Earnings Report.